Skip to main content
. Author manuscript; available in PMC: 2015 Jul 2.
Published in final edited form as: Cancer Res. 2014 Feb 7;74(8):2362–2373. doi: 10.1158/0008-5472.CAN-13-3058

Figure 3.

Figure 3

Cofilin drives TGF-β–mediated prostate cancer migration. A, human prostate cancer cells LNCaP TβRII (normal cofilin) exhibited a significant reduction in cell migration in response to TGF-β. In the presence of a neutralizing antibody against TGF-β, cell migration was restored to untreated control levels. Values shown are the number of migrating cells from two independent experiments performed in triplicate. B, S3ACFL mutation enhances prostate cancer cell migration bypassing TGF-β. Top, representative images of increased cell migration ability for S3ACFL PC-3 cells compared with WTCFL cells (24 hours). Bottom, TGF-β treatment significantly decreased WTCFL cell migration (P < 0.0008), but it had no significant effect in S3ACFL cells. Loss of TGF-β (by neutralizing antibody) restored the WTCFL PC-3 cell migration capacity, whereas it increased S3CFL-mutant cell migration (P = 0.005).